July 19, 2023
FDA: Class I recall of Quidel Triage Cardiac Panels
Editor's Note
The Food and Drug Administration (FDA), on July 17, identified the recall by Quidel Cardiovascular Inc of its Quidel Triage Cardiac Panels as Class I, the most serious.
The recall was initiated because of reports of inaccurate tests showing lower than expected troponin levels in samples. A falsely low or negative troponin level may cause a delayed or missed diagnosis of myocardial infarction.
The company reports 41 complaints, no injuries, and no deaths related to this issue.
Distribution dates: Beginning November 1, 2022.
Free Daily News
- Large-scale studies link preoperative cognition to delirium risk, reveal its deadly toll after surgery
- Socioeconomic deprivation linked to lower fitness before surgery, UK study finds
- Perioperative medication decisions need individualized risk-benefit approach
- FDA: National IV saline shortage over after years of strained supply
- FDA announces Class 1 recall for Draeger breathing filters
- Hospital CEO departures surge, boards turn to interim leadership
- Study: Attire shapes patient trust, perceptions
- ASC drill success hinges on preparation, adaptability, clear roles
- Robotic surgery shows better outcomes in select emergency colorectal cases, poised for wider use
- 5 costly mistakes to avoid when building an ASC
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement